Clinical Trials
90 trialsEpcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma
University of California, San Francisco
EPCOREâ„¢FL-2
Genmab
REMoDL-A
University Hospital Southampton NHS Foundation Trust
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
National Institutes of Health Clinical Center (CC)
ESCALADE
Acerta Pharma BV
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
University of Chicago
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
National Institutes of Health Clinical Center (CC)
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Universität des Saarlandes
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
University of Miami
Treatment and Natural History Study of Lymphomatoid Granulomatosis
National Institutes of Health Clinical Center (CC)
PACIFICO
University of Liverpool
EPCORE DLBCL-2
Genmab
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
Hoffmann-La Roche
CHRONOS-4
Bayer
Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A
Hoffmann-La Roche
Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
University of Nebraska
Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Australasian Leukaemia and Lymphoma Group
PCNSL
Memorial Sloan Kettering Cancer Center
ACCEPT
University Hospital Southampton NHS Foundation Trust
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
University of Nebraska
BRiM
Brown University
STELLAR
University of Birmingham
A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC
V+DA-EPOCH-R
Weill Medical College of Cornell University
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Hoffmann-La Roche
ZR2-CHOP
The First Affiliated Hospital with Nanjing Medical University
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
SCRI Development Innovations, LLC
ECHELON-2
Seagen Inc.
A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma
National Institute of Allergy and Infectious Diseases (NIAID)
Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members
National Institute of Allergy and Infectious Diseases (NIAID)
Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma
National Institute of Allergy and Infectious Diseases (NIAID)
Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma
Medstar Health Research Institute
Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
LYTPET
British Columbia Cancer Agency
Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma
Universität des Saarlandes
Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma
Universität des Saarlandes
Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
German High-Grade Non-Hodgkin's Lymphoma Study Group
SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL
Hoffmann-La Roche
Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger
M.D. Anderson Cancer Center
BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)
CTI BioPharma
Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL
Acrotech Biopharma Inc.
Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
Gilead Sciences
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
St. Jude Children's Research Hospital
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Seagen Inc.
Trial of DA-EPOCH Regimen for NHL With HLH
The First Affiliated Hospital with Nanjing Medical University
A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Combination Chemotherapy in Treating Patients With Lymphoma
M.D. Anderson Cancer Center
Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins